Open AccessIdentification of a Graft Versus Host Disease-Associated Human Minor Histocompatibility Antigen
Author(s) -
Joke M. M. den Haan,
Nicholas E. Sherman,
Els Blokland,
Eric L. Huczko,
Frits Koning,
Jan W. Drijfhout,
Jonathan Skipper,
Jeffrey Shabanowitz,
Donald F. Hunt,
Víctor H. Engelhard,
Els Goulmy
Publication year - 1995
Publication title -
science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 12.556
H-Index - 1186
eISSN - 1095-9203
pISSN - 0036-8075
DOI - 10.1126/science.7539551
Subject(s) - minor histocompatibility antigen , immunology , human leukocyte antigen , histocompatibility , major histocompatibility complex , antigen , biology , transplantation , cytotoxic t cell , graft versus host disease , medicine , genetics , in vitro
Minor histocompatibility antigen disparities between human leukocyte antigen (HLA)-matched bone marrow donors and recipients are a major risk factor for graft versus host disease (GVHD). An HLA-A2.1-restricted cytotoxic T cell clone that recognized the minor histocompatibility antigen HA-2 was previously isolated from a patient with severe GVHD after HLA-identical bone marrow transplantation. The HLA-A2.1-bound peptide representing HA-2 has now been identified. This peptide appears to originate from a member of the non-filament-forming class I myosin family. Because HA-2 has a phenotype frequency of 95 percent in the HLA-A2.1-positive population, it is a candidate for immunotherapeutic intervention in bone marrow transplantation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom